Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2024-07-01
Original market date: See footnote 1
2024-07-01
Product name:
VYEPTI
Description:
SINGLE-USE VIAL
DIN:
02542269
Product Monograph/Veterinary Labelling:
Date:
2025-02-11
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
LUNDBECK CANADA INC
2600 Alfred-Nobel, Suite 400
St-Laurent
Quebec
Canada
H4S 0A9
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription , Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
28:32.12
Anatomical Therapeutic Chemical (ATC): See footnote 4
N02CD05 EPTINEZUMAB
Active ingredient group (AIG) number:See footnote5
0162703001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| EPTINEZUMAB | 300 MG / 3 ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.
| Pharmacovigilance/Monitoring Activity |
|---|
| Observational Studies |